Schizophrenia Trial, Recruiting (NCT05890183)

Schizophrenia Trial, Recruiting NCT05890183 Sponsor: University of California, Los Angeles Condition: Schizophrenia

Printed from Voxsanity (voxsanity.com.au) — NCT05890183 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Schizophrenia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have experienced their first episode of a psychotic illness that began within the past three years
People who have been diagnosed (using DSM-5 criteria) with schizophrenia, schizoaffective disorder, or schizophreniform disorder
People between 18 and 45 years of age
People with enough familiarity with and fluency in English to complete the research measures accurately
People who live close enough to the UCLA Aftercare Research Program to travel there regularly

Who may not be able to join:

People whose estimated pre-illness IQ is below 70
People with a known neurological condition (such as epilepsy) or a significant history of head injury
People with evidence of a moderate or severe substance use disorder in the six months before their first psychotic episode, or whose psychosis appears to have been caused by substance use

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Keith H Nuechterlein, PhD, University of California, Los Angeles

Phone: (424) 225-1779

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05890183

Sponsor: University of California, Los Angeles

Phase: Not Applicable

Status: Recruiting

Condition: Schizophrenia

Trial contact: (424) 225-1779

More information: https://clinicaltrials.gov/study/NCT05890183

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have experienced their first episode of a psychotic illness that began within the past three years
People who have been diagnosed (using DSM-5 criteria) with schizophrenia, schizoaffective disorder, or schizophreniform disorder
People between 18 and 45 years of age
People with enough familiarity with and fluency in English to complete the research measures accurately
People who live close enough to the UCLA Aftercare Research Program to travel there regularly

Who may not be able to join:

People whose estimated pre-illness IQ is below 70
People with a known neurological condition (such as epilepsy) or a significant history of head injury
People with evidence of a moderate or severe substance use disorder in the six months before their first psychotic episode, or whose psychosis appears to have been caused by substance use

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, Los Angeles

Registry

ClinicalTrials.gov

Start date

23 May 2023

Est. completion

31 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Serum Mature BDNF; Change in Serum Mature BDNF; Change in Overall Composite T-score from the MATRICS Consensus Cognitive Battery (MCCB); Change in Overall Composite T-score from the MATRICS Consensus Cognitive Battery (MCCB); Change in Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR); Change in Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR); Attendance at Exercise Sessions for First Three Months; Attendance at Exercise Sessions for First Six Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov